Skip to Main Content
Advertisement
Open Menu
Close
About the Press
Open Menu
Our Philosophy
Our Staff
Our History
About the University
Open External Link
Contact Us
Advertise
For Librarians
Rights & Permissions
Open Menu
Permissions & Licensing
Copyright Agent
Open External Link
Publication Fees
License to Publish: Gold OA
License to Publish: Green OA
Privacy Policy
Books
Open External Link
Job Board
Open External Link
JCB
Journal of Cell Biology
JEM
Journal of Experimental Medicine
JGP
Journal of General Physiology
JHI
Journal of Human Immunity
LSA
Open External Link
Life Science Alliance
JCB
JEM
JGP
JHI
LSA
Search Dropdown Menu
header search
search input
Search input auto suggest
filter your search
All Content
All Journals
Journal of Experimental Medicine
Search
Advanced Search
User Tools Dropdown
Register
Sign In
Open Menu
Toggle Menu
Menu
Articles
Open Menu
Newest Articles
Current Issue
Browse Archive
Browse by Topic
Reviews & Opinion
Open Menu
Editorials
Found in Translation
Insights
People & Ideas
Perspectives
Reviews
Viewpoint
Collections
Open Menu
CME Articles
Special Collections
Special Focus
Email Alerts
About
Open Menu
History
Editors & Staff
Advisory Editors
Associate Editors
Reviewer Guidelines
Journal Metrics
Policies & Permissions
Advertise
Contact Us
Privacy Policy
Submit
Open Menu
Submit
Open External Link
Instructions for Authors
Publication Fees
Read & Publish Author Guide
Author Services
Open External Link
Job Board
Open External Link
Skip Nav Destination
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
J Exp Med
(2023) 220 (5): e20221952.
Currently there are no citedby results. Try again later.
Close Modal
Close Modal
This Feature Is Available To Subscribers Only
Sign In
or
Create an Account
Close Modal
Close Modal
